Trust Signals
Sources: Human RCTs and controlled trials in hepatitis, oncology, sepsis, and HIV immune reconstitution. No medspa blogs, no forum anecdotes treated as evidence.
Conflicts: FormBlends sells compounded peptides. Disagreements with the evidence are stated explicitly throughout this page.
Last reviewed: 2026-05-29
Key Takeaways
- The only dose with robust human trial support is 1.6 mg subcutaneously twice weekly, the regimen used in pivotal hepatitis B/C trials and in Zadaxin, the approved international product.
- Thymosin alpha 1 has a plasma half-life of approximately 2 hours in humans; this short window means twice-weekly dosing maintains receptor engagement through repeated pulsing, not through sustained levels.
- In sepsis ICU trials (Wu et al., Chest 2013), a dose of 1.6 mg twice daily was used for up to 5 days, representing a dramatically higher total exposure than any wellness protocol.
- Thymalin is a different substance entirely, a crude thymic extract, and its dosage data does not transfer to thymosin alpha 1.
- Freeze-thaw cycling of reconstituted peptide causes protein aggregation and measurable activity loss; this single storage error is the most common reason a legitimate batch underperforms.
What Is the Standard Thymosin Alpha 1 Dosage?
Table of Contents
- Evidence Ledger: What the Data Actually Supports
- Mechanism and Pharmacokinetics With Real Numbers
- Dosage Table by Protocol Type
- Thymosin Alpha 1 Dosage When Sick: Acute-Use Reality
- What Most Pages Get Wrong About TA-1 Dosing
- Reconstitution and Injection: Operational Guide
- Storage Chemistry: Why the Rules Matter
- Honest Head-to-Head: TA-1 vs. Alternatives
- Label and COA Literacy: How to Judge a TA-1 Product
- FAQ
Evidence Ledger: What the Data Actually Supports
Each claim rated by best available evidence type, effect direction, and confidence.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 1.6 mg SC twice weekly is effective in chronic hepatitis B (HBeAg seroconversion) | Human RCT (Chien et al., Hepatology 1998; meta-analyses) | Positive vs. placebo | High |
| 1.6 mg SC twice weekly plus interferon improves SVR in hepatitis C | Human RCTs, multiple trials | Positive (adjuvant effect) | Moderate |
| 1.6 mg twice daily reduces 28-day mortality in sepsis | Single-center RCT (Wu et al., Chest 2013, n=361) | Positive (high-severity subgroup) | Moderate |
| TA-1 improves immune markers in HIV patients | Small human controlled trials | Positive for CD4 counts | Low |
| TA-1 at any dose improves immune function in healthy adults | No RCT in healthy subjects | Unknown (extrapolated) | Very Low |
| TA-1 reduces frequency of common colds or infections in wellness users | Anecdote only; no RCT | Unproven | Very Low |
| Twice-weekly dosing maintains clinically meaningful receptor engagement | Pharmacokinetic modeling; receptor biology | Mechanistically plausible | Low |
Mechanism and Pharmacokinetics With Real Numbers
Thymosin alpha 1 (TA-1) is a 28-amino-acid polypeptide naturally secreted by thymic epithelial cells. The synthetic version is identical in sequence to the endogenous form.
How It Works
TA-1 binds Toll-like receptor 9 (TLR9) and TLR2 on dendritic cells and T cells, upregulating myeloid differentiation factor 88 (MyD88)-dependent signaling. This drives increased production of interferon-alpha and IL-12, shifts naive T cells toward Th1 phenotype, and enhances cytotoxic T-lymphocyte activity. In T-cell-depleted states (chronic viral infection, cancer), this Th1 shift is the proposed therapeutic mechanism.
Key Pharmacokinetic Numbers
- Half-life: Approximately 2 hours after subcutaneous injection in humans (Low et al., Int J Immunopharmacol 1979, the original pharmacokinetic characterization).
- Peak plasma concentration after 1.6 mg SC: Detected in the low nanomolar range within 1 to 2 hours; returns to baseline within 6 to 8 hours.
- Bioavailability (SC vs. IV): Subcutaneous bioavailability is high for small peptides of this size; the SC route is preferred in all clinical protocols over IV for outpatient use.
- Receptor engagement window: Because circulating levels decline within hours, any sustained immunological effect is driven by downstream gene expression changes (Treg modulation, dendritic cell maturation) that outlast the peptide itself, not by maintained plasma levels.
Dosage Table by Protocol Type
| Protocol Context | Dose Per Injection | Frequency | Duration | Evidence Source |
|---|---|---|---|---|
| Chronic Hepatitis B (approved use) | 1.6 mg | Twice weekly SC | 6 to 12 months | Zadaxin label; Chien et al. 1998 |
| Chronic Hepatitis C (adjuvant with interferon) | 1.6 mg | Twice weekly SC | 6 to 12 months | Multiple RCTs |
| Sepsis / Critical Illness (ICU setting only) | 1.6 mg | Twice daily SC | Up to 5 days | Wu et al., Chest 2013 |
| Cancer immune adjuvant (investigational) | 1.6 mg | Daily or twice weekly SC | Varies by trial | Multiple phase II trials |
| Wellness / immune optimization (off-label, unvalidated) | 0.5 to 1.6 mg | Two to three times weekly SC | 8 to 12 weeks, then reassess | Extrapolated; no RCT basis |
Thymosin Alpha 1 Dosage When Sick: What the ICU Data Actually Shows
This is one of the most-searched variants of the thymosin alpha 1 dosage question, and it deserves a direct answer.
The only clinical context in which a higher acute-use TA-1 dose has been tested is sepsis requiring ICU admission. Wu et al. (Chest, 2013, n=361) randomized mechanically ventilated patients with severe sepsis to 1.6 mg SC twice daily for up to 5 days alongside standard care. The treated group showed improved 28-day survival in the subgroup with severe immune suppression (monocyte HLA-DR below 30%). This is a critically ill, immunoparalyzed population, not a person with a cold or the flu at home.
What Most Pages Get Wrong About TA-1 Dosing
This is the section commodity guides skip.
1. Conflating Thymalin with Thymosin Alpha 1
Thymalin is a polypeptide extract from bovine thymus containing a mixture of uncharacterized peptides. It has its own Russian clinical literature (primarily from Khavinson and colleagues) with dosing protocols in the 10 to 20 mg range. These numbers are not transferable to thymosin alpha 1, which is a single, sequenced, synthetic 28-amino-acid molecule. Dozens of wellness pages cite "thymalin peptide dosage" interchangeably with TA-1 dosage. They are wrong.
2. Treating Animal Study Doses as Human Equivalents
Several murine studies use weight-based doses that, when naively converted to a 70 kg human, suggest much higher doses than 1.6 mg. Rodent immune system scaling, route differences, and endpoint differences make these conversions unreliable. The FDA's body-surface-area allometric scaling factor (Km = 3 for mice, 37 for humans) means a 1 mg/kg mouse dose does not simply equal 1 mg/kg in humans.
3. Claiming Subcutaneous and Intramuscular Are Equivalent
All published human TA-1 pharmacokinetics use subcutaneous injection. Intramuscular injection of peptides alters absorption rate, local depot formation, and potentially immunogenicity. No IM pharmacokinetic data exists for TA-1. Recommending IM as an alternative is unsupported.
4. Ignoring the Reconstitution Volume Math
A 10 mg vial reconstituted with 1 mL bacteriostatic water yields 10 mg/mL, meaning a 1.6 mg dose is 0.16 mL, difficult to measure accurately in a standard insulin syringe. Reconstituting with 2 mL (5 mg/mL) makes the 1.6 mg dose 0.32 mL, which is measurable with standard graduations. This math matters for dose accuracy and most guides never show it.
Reconstitution and Injection: Operational Guide
What You Need
- Bacteriostatic water for injection (not sterile water; the benzyl alcohol preservative extends multi-use vial life)
- 27 to 29 gauge, 0.5-inch insulin syringe
- Alcohol swabs (70% isopropyl alcohol)
- Sharps disposal container
Reconstitution Math Table
| Vial Size | Bacteriostatic Water Added | Concentration | Volume per 1.6 mg Dose |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 0.32 mL |
| 10 mg | 2 mL | 5 mg/mL | 0.32 mL |
| 10 mg | 4 mL | 2.5 mg/mL | 0.64 mL |
Injection Technique
- Wipe the vial stopper with an alcohol swab and allow it to dry fully (approximately 30 seconds).
- Insert the needle at a 45 to 90 degree angle into the subcutaneous fat layer (pinch skin if lean).
- Inject slowly, withdraw, and apply gentle pressure. Do not rub (can disperse the peptide unevenly).
- Rotate injection sites: abdomen at least 2 inches from the navel, outer thigh, lateral flank.
Storage Chemistry: Why the Rules Are Not Arbitrary
This explains the mechanism behind each storage rule so you can make informed decisions when conditions are imperfect.
Why Lyophilized Powder Is Stable but Reconstituted Solution Is Not
In lyophilized (freeze-dried) form, the peptide backbone is immobilized in a glassy excipient matrix with very low water activity. Hydrolysis of peptide bonds requires free water. Remove the water and you arrest the primary degradation pathway. At 2 to 8 degrees Celsius, lyophilized TA-1 retains activity for the duration stated on most manufacturers' COAs (commonly 2 years).
Once water is added during reconstitution, hydrolysis and oxidation become active. Methionine residues (TA-1 does not contain methionine, so oxidative risk is lower than for some other peptides, but deamidation of asparagine or glutamine residues is still possible over weeks). The benzyl alcohol in bacteriostatic water does not prevent chemical degradation; it prevents microbial growth only. Chemical degradation is temperature-dependent and follows Arrhenius kinetics: every 10 degrees Celsius increase roughly doubles the reaction rate. This is why refrigerator temperature (4 degrees Celsius) extends post-reconstitution stability compared to room temperature.
Why Freeze-Thaw Cycling Destroys Reconstituted Peptide
When a reconstituted peptide solution freezes, ice crystals form and concentrate the solute. The local pH can shift, and proteins and peptides can aggregate at the ice-liquid interface. Upon thawing, these aggregates do not fully resolubilize, yielding a solution with lower active monomer content and potentially immunogenic aggregates. This is not unique to TA-1; it is a universal peptide and protein formulation problem.
Practical rule: If you need to store beyond 30 days, keep the vial lyophilized and unreconstituted. Once reconstituted, do not freeze; use within 30 days from refrigerator.
Honest Head-to-Head: Thymosin Alpha 1 vs. Alternatives
| Dimension | Thymosin Alpha 1 (1.6 mg SC) | BPC-157 (systemic immune claims) | Low-Dose Naltrexone (LDN) | Zinc / Vitamin D (immune baseline) |
|---|---|---|---|---|
| Human RCT evidence for immune outcomes | Yes, for viral hepatitis and sepsis | No human RCT for immune endpoints | Yes, for autoimmune conditions (MS, fibromyalgia) | Yes, for deficiency correction |
| Regulatory status (USA) | Compounded only; no FDA approval | Compounded only; no FDA approval | Off-label FDA-approved drug | OTC supplement (GRAS) |
| Route of administration | Subcutaneous injection | Injection or oral | Oral tablet | Oral |
| Cost (monthly, approximate) | Moderate to high ($80 to $200+) | Moderate ($40 to $100) | Low ($20 to $50) | Very low ($5 to $20) |
| Evidence for healthy-adult immune optimization | None (extrapolated) | None | Minimal | Moderate (if deficient) |
| Where TA-1 wins | Chronic viral infection (HBV/HCV), adjuvant oncology, immunoparalysis | TA-1 has the strongest human clinical evidence base of any peptide in this category | ||
| Where TA-1 loses | For healthy adults seeking general immune support, zinc/vitamin D correcting a documented deficiency has stronger cost-benefit evidence than TA-1 | |||
Label and COA Literacy: How to Judge a TA-1 Product
A certificate of analysis (COA) is only as useful as you can read it. Here is what to demand and what each item means.
- HPLC purity: Should be greater than 98% for a research-grade peptide. HPLC measures the ratio of the target peak to all peaks; a 95% HPLC result means 5% is unknown material.
- Molecular weight confirmation: TA-1 has a molecular weight of 3108.4 Da. Mass spectrometry (MS) on the COA should confirm this within instrument tolerance. If the COA shows a mass spectrometry result differing meaningfully from this, the sequence may be wrong.
- Sequence verification: Ideally the COA states the 28-amino-acid sequence was confirmed. The sequence is: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.
- Endotoxin testing (LAL test): Bacterial endotoxins are the most common contaminant in peptides synthesized via solid-phase methods. An endotoxin level below 1 EU/mg is the standard threshold for parenteral research use. Many consumer-grade COAs omit this test. Its absence is a red flag for an injectable product.
- Sterility: Compounded injectables should carry a sterility test result or be produced under ISO 5 (Class 100) conditions. A COA that only lists HPLC purity with no endotoxin or sterility data is insufficient for a subcutaneous injectable.
- What a degraded product looks like: Reconstituted TA-1 should be clear and colorless. Cloudiness, visible particles, or a yellow tint indicates aggregation, contamination, or degradation. Discard; do not inject.
Frequently Asked Questions
Sources
- Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology.
Related peptide guides